跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
RA-II
首页
药物
RA-II
RA-II
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
COMPOSITIONS AND METHODS OF TREATING LUPUS NEPHRITIS
EP 3936524 A3
申请人: HOFFMANN LA ROCHE
优先权: 2015
CN
EP
US
7 件公开
Isotope purification method
US 10729794 B2
申请人: BAYER AS
优先权: 2016
CN
EP
US
WO
5 件公开
Organic molecules for use in optoelectronic devices
US 12378226 B2
申请人: SAMSUNG DISPLAY CO LTD
优先权: 2017
CN
EP
US
WO
5 件公开
Compounds for imaging tau proteins that accumulate in brain
US 11667628 B2
申请人: NATIONAL INSTITUTES FOR QUANTUM AND RADIOLOGICAL SCIENCE AND TECH
优先权: 2012
CN
US
5 件公开
NOVEL TRPV3 MODULATORS
EP 2771322 A2
申请人: ABBVIE INC
优先权: 2011
EP
US
WO
4 件公开
Urea oligomers, the preparation method thereof and pharmaceutical composition containing same
US 7691899 B2
申请人: CENTRE NAT RECH SCIENT
优先权: 2001
US
4 件公开
Estrogen receptor modulators and uses thereof
US 7989487 B2
申请人: UNIV NEW JERSEY MED
优先权: 2007
US
4 件公开
ORGANIC MOLECULES FOR OPTOELECTRONIC DEVICES
EP 3844245 A1
申请人: CYNORA GMBH
优先权: 2018
CN
EP
WO
3 件公开
CN 110272411 A
申请人: CYNORA GMBH
优先权: 2018
CN
3-[3-AMINO-6-(2-HYDROXYPHENYL)PYRIDAZIN-4-YL]-3,8-DIAZABICYCLO[3.2.1]OCTANE DERIVATIVES AS SMARCA2 DEGRADING PROTACS FOR THE TREATMENT OF CANCER
EP 4727945 A1
申请人: ASTRAZENECA AB
优先权: 2023
CN
EP
WO
3 件公开
PHARMACEUTICAL FORMULATION OF GLUCAGON-LIKE PEPTIDE -1 RECEPTOR AGONIST PEPTIDE FOR SUBLINGUAL DELIVERY
US 20250241994 A1
申请人: IMMUNWORK INC
优先权: 2024
CN
US
WO
3 件公开
第 1 / 10 页
上一页
下一页
药物
反馈